摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2,3-dimethoxybenzyl)aminoacetaldehyde diethyl acetal | 53762-16-6

中文名称
——
中文别名
——
英文名称
N-(2,3-dimethoxybenzyl)aminoacetaldehyde diethyl acetal
英文别名
dimethoxy-2,3 benzylaminoacetal diethylique;(2,2-diethoxy-ethyl)-(2,3-dimethoxy-benzyl)-amine;(2,3-dimethoxy-benzylamino)-acetaldehyde diethyl acetal;N-(2,3-dimethoxybenzyl)-2,2-diethoxyethanamine;N-[(2,3-dimethoxyphenyl)methyl]-2,2-diethoxyethanamine
N-(2,3-dimethoxybenzyl)aminoacetaldehyde diethyl acetal化学式
CAS
53762-16-6
化学式
C15H25NO4
mdl
——
分子量
283.368
InChiKey
BCQDFNHNUDHENS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    352.3±37.0 °C(Predicted)
  • 密度:
    1.031±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    20
  • 可旋转键数:
    10
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    49
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS<br/>[FR] ISOQUINOLÉINES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE POLYMÉRISATION DES TUBULINES
    申请人:EXONHIT S A
    公开号:WO2011151423A1
    公开(公告)日:2011-12-08
    The present invention relates generally to substituted isoquinolines and their use as tubulin polymerization inhibitors. In particular, the invention relates to substituted isoquinolines which possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.
    本发明总体上涉及取代异喹啉及其作为微管蛋白聚合抑制剂的应用。特别是,本发明涉及具有有用的治疗活性的取代异喹啉,这些化合物在治疗方法、药物制造以及含有这些化合物的组合物中的应用。
  • 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline Derivatives. II. Their Renal Vasodilation Activity and Structure-Activity Relationship.
    作者:Hideki ANAN、Akihiro TANAKA、Ryuji TSUZUKI、Masaki YOKOTA、Takeyuki YATSU、Takashi FUJIKURA
    DOI:10.1248/cpb.44.1865
    日期:——
    A series of 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives showed potent DA1 agonistic activities. We investigated the structure-activity relationship of the racemic compounds of this series. 4-(3,4-Dihydroxyphenyl)-7-methanesulfonamido-1,2,3,4-tetrahydroiso quinoline (43) was identified as a potent renal vasodilator with activity almost equal to that of YM435 (1).
    一系列的4-(3,4-二羟基苯基)-1,2,3,4-四氢异喹啉衍生物显示出强大的DA1激动活性。我们研究了该系列外消旋化合物的构效关系。4-(3,4-二羟基苯基)-7-甲磺酰胺基-1,2,3,4-四氢异喹啉(43)被确定为有效的肾血管扩张药,其活性几乎与YM435(1)相等。
  • Synthesis of new substituted 7,12-dihydro-6,12-methanodibenzo[<i>c,f</i>]azocine-5-carboxylic acids containing a tetracyclic tetrahydroisoquinoline core structure
    作者:Agnieszka Grajewska、Maria Chrzanowska、Wiktoria Adamska
    DOI:10.3762/bjoc.17.168
    日期:——
    A convenient and simple protocol has been developed for the synthesis of a series of new tetracyclic tetrahydroisoquinoline derivatives, 7,12-dihydro-6,12-methanodibenzo[c,f]-azocine-5-carboxylic acids by three component Petasis reaction with the use of aminoacetaldehyde acetals bearing substituted benzyl groups as the amine components followed by Pomeranz–Fritsch double cyclization reaction. By applying
    开发了一种方便、简单的方案,通过三组分 Petasis 反应合成一系列新型四环四氢异喹啉衍生物 7,12-二氢-6,12-亚甲基二苯并[ c,f ]-偶氮辛-5-羧酸。使用带有取代苄基的氨基乙醛缩醛作为胺组分,然后进行 Pomeranz-Fritsch 双环化反应。通过应用该方法,已经以令人满意的收率制备了几种酸。观察到 Petasis 反应产物在稀 HCl 溶液中形成苯基甘氨酸衍生物的前所未有的化学行为,并提出了解释这种反应性的机制。
  • REVERSE-TURN MIMETICS AND METHOD RELATING THERETO
    申请人:Moon Sung Hwan
    公开号:US20100222303A1
    公开(公告)日:2010-09-02
    Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    本发明揭示了限制构象的化合物,其模拟生物活性肽和蛋白质的反转区域的二级结构以及它们的前药。这种反转区域模拟结构和前药在广泛的领域中具有实用性,包括用作诊断和治疗剂。本发明还揭示了包含这种反转区域模拟结构的库以及筛选相同以识别生物活性成员的方法。本发明还涉及使用这种化合物和前药来抑制或治疗由Wnt信号通路调节的疾病,例如癌症,特别是结肠直肠癌,与血管成形术相关的再狭窄,多囊肾病,异常血管生成疾病,类风湿性关节炎疾病,结节性硬化症,阿尔茨海默病,过度生长或脱发,或溃疡性结肠炎。
  • Reverse-turn mimetics and method relating thereto
    申请人:Choongwae Pharma Corporation
    公开号:US08138337B2
    公开(公告)日:2012-03-20
    Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    本发明揭示了构象受限化合物,其模拟生物活性肽和蛋白质的反转区域的二级结构,以及它们的前药。这样的反转区模拟结构和前药在广泛的领域中具有实用性,包括用作诊断和治疗剂。本发明还揭示了包含这些反转区模拟结构的库,以及筛选这些库以识别生物活性成员的方法。本发明还涉及使用这样的化合物和前药来抑制或治疗由Wnt信号通路调节的疾病,如癌症,特别是结肠直肠癌,与血管成形术相关的再狭窄,多囊肾病,异常血管生成疾病,类风湿性关节炎疾病,结节性硬化症,阿尔茨海默病,过度毛发生长或脱发,或溃疡性结肠炎。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐